Featured Research

from universities, journals, and other organizations

Popular Anti-epileptic Drug Also Effective In Controlling Debilitating Symptom Of Multiple Sclerosis

Date:
December 18, 2003
Source:
University Of Texas Southwestern Medical Center At Dallas
Summary:
A study published in the December issue of Archives of Neurology and currently available online shows that levetiracetam reduced phasic spasticity, which is marked by spasms and painful muscle cramps, in 100 percent of patients in a small clinical study.

A study published in the December issue of Archives of Neurology and currently available online shows that levetiracetam reduced phasic spasticity, which is marked by spasms and painful muscle cramps, in 100 percent of patients in a small clinical study.

"It's amazing how many MS patients can't walk, can't move, and you treat their spasticity and they're fine," said Dr. Kathleen Hawker, assistant professor of neurology at UT Southwestern and lead author of the study. "What's nice about these drugs is that they also work for nerve pain, which in turn improves the patient's mood, so we can use one drug for three things instead of prescribing pain killers and antidepressants in addition to the spasticity therapies."

Spasticity is often seen in patients with MS and amyotrophic lateral sclerosis (ALS), as well as after a stroke or spinal-cord injury. It can lead to loss of balance, increased risk of falls, pain, fatigue, and walking difficulties.

Drugs currently used to treat spasticity may cause memory problems, weakness and lethargy in some patients.

"We're trying to look at medicines that can be used for multiple symptoms so we don't get into a lot of drug interactions," Dr. Hawker said. "If we can get the same results with a better-tolerated drug, that's great for our patients."

Researchers examined the histories of 11 patients treated with levetiracetam between January 2001 and June 2002 for MS-related spasticity at Southwestern Medical Center. The patients were treated with levetiracetam for one to four months, with dosages starting at 250 milligrams per day and increasing to 3,000 mg per day. Researchers found that leviteracetam decreased phasic spasticity in patients taking the drug alone as well as in those who took it in combination with other therapies for spasticity. Tonic spasticity, which produces stiffness, did not improve. Overall, the clinical investigators found the side effects of levetiracetam to be generally mild, Dr. Hawker said.

Multiple sclerosis is the most common disabling disease of young people, ages 18 to 45, and affects 350,000 people in the United States. Symptoms of the disease are unpredictable, vary by individual, and often come and go. While one patient may experience severe vision problems, another may have abnormal fatigue. Other symptoms include loss of balance and muscle coordination, slurred speech, tremors, stiffness, and bladder problems.

Dr. Elliot Frohman, head of UT Southwestern's multiple sclerosis program and associate professor of neurology and ophthalmology, and Dr. Michael Racke, associate professor of neurology and in the Center for Immunology, also participated in the study, which was partially funded by UCB Pharma, Inc.


Story Source:

The above story is based on materials provided by University Of Texas Southwestern Medical Center At Dallas. Note: Materials may be edited for content and length.


Cite This Page:

University Of Texas Southwestern Medical Center At Dallas. "Popular Anti-epileptic Drug Also Effective In Controlling Debilitating Symptom Of Multiple Sclerosis." ScienceDaily. ScienceDaily, 18 December 2003. <www.sciencedaily.com/releases/2003/12/031217073436.htm>.
University Of Texas Southwestern Medical Center At Dallas. (2003, December 18). Popular Anti-epileptic Drug Also Effective In Controlling Debilitating Symptom Of Multiple Sclerosis. ScienceDaily. Retrieved August 2, 2014 from www.sciencedaily.com/releases/2003/12/031217073436.htm
University Of Texas Southwestern Medical Center At Dallas. "Popular Anti-epileptic Drug Also Effective In Controlling Debilitating Symptom Of Multiple Sclerosis." ScienceDaily. www.sciencedaily.com/releases/2003/12/031217073436.htm (accessed August 2, 2014).

Share This




More Health & Medicine News

Saturday, August 2, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Texas Quintuplets Head Home

Texas Quintuplets Head Home

Reuters - US Online Video (Aug. 1, 2014) After four months in the hospital, the first quintuplets to be born at Baylor University Medical Center head home. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
Ebola Patient Coming to U.S. for Treatment

Ebola Patient Coming to U.S. for Treatment

Reuters - US Online Video (Aug. 1, 2014) A U.S. aid worker infected with Ebola while working in West Africa will be treated in a high security ward at Emory University in Atlanta. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
Ebola Vaccine Might Be Coming, But Where's It Been?

Ebola Vaccine Might Be Coming, But Where's It Been?

Newsy (Aug. 1, 2014) Health officials are working to fast-track a vaccine — the West-African Ebola outbreak has killed more than 700. But why didn't we already have one? Video provided by Newsy
Powered by NewsLook.com
Study Links Certain Birth Control Pills To Breast Cancer

Study Links Certain Birth Control Pills To Breast Cancer

Newsy (Aug. 1, 2014) Previous studies have made the link between birth control and breast cancer, but the latest makes the link to high-estrogen oral contraceptives. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins